ICD-10-CM Chapter 2: Neoplasms (C00-D49) The neoplasm chapter contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms such as prostatic adenomas maybe found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant or of uncertain …
ICD-10-CM Codes in this Guideline. Malignant neoplasms of lip, oral cavity and pharynx (C00-C14) Malignant neoplasms of digestive organs (C15-C26) Malignant neoplasms of respiratory and intrathoracic organs (C30-C39) Malignant neoplasms of bone and articular cartilage (C40-C41) Melanoma and other malignant neoplasms of skin (C43-C44)
In ICD-10-CM both polycythemia and secondary polycythemia are reported with code D75.1 from chapter 3, "Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the Immune Mechanism." If the physician documents polycythemia vera, then ICD-10-CM code D45 from the neoplasms chapter is reported.
C50.011 Malignant neoplasm of nipple and areola, right female breast. C50.012 Malignant neoplasm of nipple and areola, left female breast. C50.019 Malignant neoplasm of nipple and areola, unspecified female breast. C50.02 Malignant neoplasm of nipple and areola, male.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, ...
Malignant neoplasm of retroperitoneum and peritoneum (C48)
Malignant neoplasm of other and unsp female genital organs (C57)
Malignant neoplasm of other and unspecified parts of mouth (C06)
Malignant neoplasm of eye and adnexa (C69)
Malignant neoplasm of base of tongue (C01)
Neoplasms (C00–D48) All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. ...
Classification of neoplasms is primarily by site ( topography) with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code.
The Neoplasm Table gives the code numbers for neoplasm by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in-situ, of uncertain behavior or of unspecified nature. When such descriptors are not present, the reminder of the alphabetical index should be consulted.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4: Endocrine, Nutritional and Metabolic Disease may be used to identify functional activity associated with any neoplasm.
The neoplasm chapter contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms such as prostatic adenomas maybe found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant or of uncertain histologic behavior.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
If a patient admission/encounter is solely for the administration of chemotherapy, immunotherapy or radiation therapy assign code Z51.0, Encounter for antineoplastic radiation therapy, or Z51.11, Encounter for antineoplastic chemotherapy, or Z51.12, Encounter for antineoplastic immunotherapy as the first-listed or principal diagnosis. If a patient receives more than one of these therapies during the same admission more than one of these codes may be assigned, in any sequence. The malignancy for which the therapy is being administered should be assigned as a secondary diagnosis.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
When a patient is admitted for the purpose of radiotherapy, immunotherapy or chemotherapy and develops complications such as uncontrolled nausea and vomiting or dehydration, the principal or first-listed diagnosis is Z51.0, Encounter for antineoplastic radiation therapy , or Z51.11, Encounter for antineoplastic chemotherapy, or Z51.12, Encounter for antineoplastic immunotherapy followed by any codes for the complications.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
When the admission/encounter is for management of an anemia associated with an adverse effect of the administration of chemotherapy or immunotherapy and the only treatment is for the anemia, the anemia code is sequenced first followed by the appropriate codes for the neoplasm and the adverse effect ( T45.1X5, Adverse effect of antineoplastic and immunosuppressive drugs). When the admission/encounter is for management of an anemia associated with an adverse effect of radiotherapy, the anemia code should be sequenced first, followed by the appropriate neoplasm code and code Y84.2, Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure.
Code C80.1, Malignant (primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting.
Chapter 2 in ICD-10-CM contains more than 1,540 codes found in categories C00–D49, starting with category C00, which contains codes for malignant neoplasm of the lip.
When admission/encounter is for management of an anemia associated with the malignancy, and the treatment is only for anemia, the appropriate code for the malignancy is sequenced as the principal or first-listed diagnosis followed by code D63.0, Anemia in neoplastic disease.
ICD-10-CM codes provide greater detail than ICD-9-CM codes for reporting neoplasms. In many instances, ICD-10-CM neoplasm codes can provide information on whether a neoplasm occurred in a right-sided or left-sided body part. ICD-10-CM also provides codes for reporting neoplasm sites with greater precision. In some instances, ICD-10-CM provides greater detail on the type of neoplasm for malignant neoplasms and for benign and other histologic behaviors.
In ICD-9-CM both polycythemia and polycythemia vera are reported with code 238.4 from chapter 2, "Neoplasms." If the physician documents secondary polycythemia, then ICD-9-CM code 289.0 from the "Diseases of the Blood and Blood-forming Organs" chapter is reported.
In ICD-9-CM, vera is a nonessential modifier to polycythemia. That is not the case in ICD-10-CM, where polycythemia vera is coded differently than polycythemia.
Because neoplasms can occur anywhere in the body , coding professionals might wonder where to begin refreshing their anatomy and pathophysiology knowledge. The section below examines a few of the changes that will occur between ICD-9-CM and ICD-10-CM neoplasm codes, with a focus on areas in which knowledge of anatomy and pathophysiology will be particularly helpful.
A malignant neoplasm in which there is infiltration of the skin overlying the breast by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (paget cells). It is almost always associated with an intraductal or invasive ductal carcinoma of the breast.
genes - there are two genes, brca1 and brca2, that greatly increase the risk. Women who have family members with breast or ovarian cancer may wish to be tested.
An intraductal carcinoma of the breast extending to involve the nipple and areola, characterized clinically by eczema-like inflammatory skin changes and histologically by infiltration of the dermis by malignant cells (paget's cells). (Dorland, 27th ed) Breast cancer affects one in eight women during their lives.
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C50. A type 1 excludes note is for used for when two conditions cannot occur together , such as a congenital form versus an acquired form of the same condition. skin of breast (.